交银国际发表研究报告指，康方生物(09926.HK) 去年及去年下半年的业绩胜预期，列账纯利及non-IFRS(非国际财务报告准则)纯利或有可能在今年末首次同录得正数。该行下调对其今明两年的收入预测分别6%及4%，至33亿元人民币(下同)及52亿元。另外，该行目前预期公司可在今年末录得列账纯利2,300万元，以及non-IFRS纯利1.03亿元；同时亦上调了2026年经调整盈利预测3%至12亿元。
考虑临床展望及基本面更明朗，该行将公司目标价由85港元上调至90港元，维持评级“跑赢大市”。(vc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-01 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.